Welcome to our dedicated page for Microbot Medical news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) announced on March 13, 2023, that Dr. Stavros Spiliopoulos has joined its Scientific Advisory Board. As an internationally recognized interventional radiologist, Dr. Spiliopoulos's expertise will bolster the company's efforts to advance the LIBERTY® Robotic System towards regulatory approval and commercialization. His extensive experience in vascular interventional radiology and numerous awards further solidify his role. The addition reflects Microbot's ongoing strategy to enhance clinical awareness and establish centers of excellence in key growth markets in Europe and the Americas.
Microbot Medical (Nasdaq: MBOT) has announced that an abstract detailing the LIBERTY Robotic System will be presented at the Israeli Conference on Robotics on March 28, 2023. Dr. Eyal Morag, the company's Chief Medical Officer, will discuss the advantages of this single-use endovascular robotic system over traditional methods, highlighting reduced physician radiation exposure and physical stress. The presentation will include findings from animal feasibility studies showcasing performance and safety metrics. The conference serves as a major event for robotics advancements across various sectors, including healthcare.
Microbot Medical (Nasdaq: MBOT), recognized for developing the LIBERTY® Robotic System, has received a non-dilutive grant of 300,000 NIS from Israel's Ministry of Economy. This funding is part of the 'Smart Money' program aimed at enhancing the commercialization of its robotic system in the U.S. market. CFO Rachel Vaknin emphasized that this grant will boost marketing efforts and foster engagement with key stakeholders as the company approaches crucial regulatory and clinical phases. The grant may be repaid through future royalties from LIBERTY sales, marking a significant step toward increasing market awareness and anticipation for the product's launch.
Microbot Medical Inc. (MBOT) continues to promote its LIBERTY® Robotic System, the first single-use endovascular robotic system, ahead of its commercialization. At the upcoming Society of Interventional Radiologists (SIR) annual meeting from March 4-9 in Phoenix, Arizona, CEO Harel Gadot and other executives will engage with potential partners and leading interventional radiologists. The company aims to gather feedback to enhance user experience and improve patient care standards. Microbot specializes in micro-robotic technologies and aims to transform medical outcomes.
Microbot Medical Inc. (MBOT) has expanded its Scientific Advisory Board (SAB) by adding Dr. Francisco C. Carnevale, making a total of 13 Key Opinion Leaders globally. This strategic move enhances support for the regulatory and commercialization efforts of the LIBERTY® Robotic System. Dr. Carnevale, a notable vascular radiologist from Brazil, brings extensive expertise in Prostatic Artery Embolization. CEO Harel Gadot emphasized the importance of attracting global physicians to validate and advance the system’s clinical and economic advantages. The addition aims to broaden the technology's interventional applications and improve accessibility.
Microbot Medical Inc. (NASDAQ: MBOT) has announced the issuance of a new design patent for its LIBERTY® Robotic System's remote controller by the Japan Patent Office. This patent complements existing design patents in the U.S. and Europe, bolstering the company’s intellectual property portfolio. The LIBERTY system allows endovascular procedures to be performed remotely, which may reduce radiation exposure and physical strain for healthcare providers. Feedback from recent studies indicates that this innovative design enhances user experience, facilitating better patient care.
Microbot Medical (Nasdaq: MBOT) announced its upcoming webinar, “Access-Ability Live by MBOT,” scheduled for February 8, 2023, at 1:00 PM ET. Hosted by Dr. Eyal Morag, the event will feature Dr. Giora Weisz, a leading interventional cardiologist, discussing the evolving landscape of endovascular robotics and the role of robotic systems in cardiovascular procedures. This initiative aims to engage stakeholders in the field and highlight current innovations and challenges. The webinar is part of Microbot's ongoing effort to address key topics in healthcare and endovascular technologies.
Microbot Medical (NASDAQ: MBOT) announced a webinar titled Access-Ability Live by MBOT, scheduled for January 10, 2023. The event, moderated by Joe Mullings, will bring together experts from the medtech sector to discuss advancements in endovascular robotics and unmet medical needs. This series aims to facilitate discussions on critical topics in healthcare. Microbot focuses on developing pioneering micro-robotic technologies to improve patient outcomes. The firm’s approach includes a strong emphasis on innovation in endovascular procedures.
Microbot Medical (NASDAQ: MBOT) announced the upcoming webinar, "Access-Ability Live by MBOT," on December 21, 2022, at 1:00 PM ET. Dr. Eyal Morag will host Dr. Ripal Gandhi, an expert in endovascular robotics, who will discuss his experiences with robotic surgical procedures. The series aims to engage stakeholders in discussions on critical healthcare topics. Microbot is known for its innovative LIBERTY® Robotic System, focusing on micro-robotic technologies for medical applications. For more information, visit Microbot Medical.
Microbot Medical (Nasdaq: MBOT) has secured its third patent for the LIBERTY® Robotic System in Israel, bringing its total global patents for the system to ten. This patent enhances its intellectual property portfolio and is seen as a vital step towards regulatory approval and global commercialization. Chairman and CEO Harel Gadot emphasized the strategic importance of expanding the IP portfolio to maintain a competitive edge in key markets while progressing towards regulatory milestones and product release.